Skip to main content
STS 2024 Annual Meeting Main banner

Brendon Stiles, MD

Montefiore Health System / Albert Einstein School of Medicine
Bronx, New York, United States

Presentation(s):

  • Adjuvant Lung Cancer Trials

    Saturday, January 27, 2024
    10:07 AM - 10:17 AM CT

    Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

  • Tumor Board Discussion

    Saturday, January 27, 2024
    10:51 AM - 11:15 AM CT

    Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

  • Equity in Standard of Care Treatment -- Patient Navigation in Lung Cancer

    Saturday, January 27, 2024
    9:50 AM - 10:00 AM CT

    Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

  • Lung Cancer Tumor Board: Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK- Targeted Strategies Tell Us?

    Saturday, January 27, 2024
    5:45 PM - 7:15 PM CT

    Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

  • CME/MOC Credit: Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

    Sunday, January 28, 2024
    11:40 AM - 12:40 PM CT

    Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Email Brendon